Stem Point Capital LP Taysha Gene Therapies, Inc. Transaction History
Stem Point Capital LP
- $499 Billion
- Q3 2025
A detailed history of Stem Point Capital LP transactions in Taysha Gene Therapies, Inc. stock. As of the latest transaction made, Stem Point Capital LP holds 839,669 shares of TSHA stock, worth $3.54 Million. This represents 0.55% of its overall portfolio holdings.
Number of Shares
839,669
Previous 1,203,941
30.26%
Holding current value
$3.54 Million
Previous $2.78 Billion
1.27%
% of portfolio
0.55%
Previous 0.89%
Shares
3 transactions
Others Institutions Holding TSHA
# of Institutions
161Shares Held
247MCall Options Held
463KPut Options Held
246K-
Rtw Investments, LP New York, NY24.4MShares$103 Million1.03% of portfolio
-
Ra Capital Management, L.P. Boston, MA23.6MShares$99.2 Million1.27% of portfolio
-
Avoro Capital Advisors LLC New York, NY21.7MShares$91.4 Million0.93% of portfolio
-
Morgan Stanley New York, NY19.3MShares$81.3 Million0.0% of portfolio
-
Goldman Sachs Group Inc New York, NY13.4MShares$56.3 Million0.01% of portfolio
About Taysha Gene Therapies, Inc.
- Ticker TSHA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 48,359,500
- Market Cap $204M
- Description
- Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for th...